Skip to main content

EPO

No sources yet

An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.

Source summary generated November 6, 2026; this date does not indicate completed review.

HormonesAliases: Erythropoietin, epoetin, epoetin alfa, rhEPO, Epogen
Track your own protocol free →

Quotes from three independent practitioners, with their sources. Research context only.

What it is and how it works

From the published literature on EPO; the papers are listed at the end. Research summary, not a recommendation.

What it is

EPO (erythropoietin) is a glycoprotein hormone, a protein with sugar chains attached, made mainly by the kidney in response to low oxygen. It tells the bone marrow to make red blood cells. Recombinant human versions (epoetin alfa, epoetin beta and longer-acting darbepoetin alfa) are approved medicines; the first FDA approval of epoetin alfa (Epogen) was in 1989 according to its current label.

How it works

EPO binds the EPO receptor on red-blood-cell precursors in the bone marrow, which keeps those cells alive and lets them mature into red cells, raising the blood's oxygen-carrying capacity. Production of the hormone is switched on by HIF (hypoxia-inducible factor), a protein complex that rises when oxygen is low. Because hemoglobin mass is a key limit on aerobic performance, EPO has also been misused by endurance athletes; recombinant EPO can be detected because its sugar-chain pattern differs from the body's own.

What it has been studied for

  • Anemia in chronic kidney disease, where the kidney makes too little EPO (meta-analysis and large trials)
  • Choosing hemoglobin targets in kidney disease (three large randomized trials)
  • Chemotherapy-associated anemia in cancer (clinical guideline)
  • Blood doping in sport and its detection (reviews)

Strength of the evidence

Approved drugEpoetin alfa and darbepoetin alfa are FDA-approved products supported by many randomized trials and a Cochrane network meta-analysis.

What the literature reports on safety

The Epogen label carries a boxed warning that ESAs (erythropoiesis-stimulating agents) increase the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access and tumor progression or recurrence, and advises the lowest dose that avoids transfusions. Large trials in kidney disease found more cardiovascular harm with higher hemoglobin targets. Published copies of the 2026 WADA Prohibited List name erythropoietins and darbepoetins among prohibited erythropoietin receptor agonists (section S2.1.1).

Key papers

  1. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. (opens in a new tab)

    Review · Chung EY, Palmer SC, et al. · Cochrane Database of Systematic Reviews (2023) · PMID 36791280

    Across 117 studies with 25,237 adults, epoetin alfa and darbepoetin alfa reduced the need for blood transfusions compared with placebo, but effects on death were uncertain and most studies had bias concerns.

  2. Erythropoietin. (opens in a new tab)

    Review · Jelkmann W · Frontiers of Hormone Research (2016) · PMID 27348128

    Reviewed how EPO regulates red-cell production and how it can be misused by athletes, noting recombinant forms are chemically detectable but newer EPO-raising drugs make anti-doping control harder.

  3. Correction of anemia with epoetin alfa in chronic kidney disease. (opens in a new tab)

    Randomized trial · Singh AK, Szczech L, et al. · New England Journal of Medicine (2006) · PMID 17108343

    In 1,432 patients with chronic kidney disease, a higher hemoglobin target with epoetin alfa carried more risk of death, heart attack, heart failure hospitalization or stroke, with no added quality-of-life gain.

  4. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. (opens in a new tab)

    Randomized trial · Drüeke TB, Locatelli F, et al. · New England Journal of Medicine (2006) · PMID 17108342

    In 603 patients given epoetin beta, aiming for a normal hemoglobin did not reduce cardiovascular events versus a lower target, and more patients needed dialysis in the normal-target group.

  5. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. (opens in a new tab)

    Randomized trial · Pfeffer MA, Burdmann EA, et al. · New England Journal of Medicine (2009) · PMID 19880844

    In 4,038 patients, darbepoetin alfa reduced transfusions but did not lower death or cardiovascular events and nearly doubled the stroke rate.

  6. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. (opens in a new tab)

    Review · Bohlius J, Bohlke K, et al. · Journal of Clinical Oncology (2019) · PMID 30969847

    The cancer societies' guideline reviewed 15 meta-analyses and two trials to update when these agents may be used for chemotherapy-associated anemia.

  7. Blood doping and its detection. (opens in a new tab)

    Review · Jelkmann W, Lundby C · Blood (2011) · PMID 21652677

    Reviewed how blood doping with recombinant erythropoietic proteins is detected, including the athlete biological passport that tracks red-cell parameters over time.

Sources checked: PubMed (E-utilities abstracts for every PMID), DailyMed Epogen label and Amgen prescribing information (boxed warning, initial approval year), published copies of the WADA 2026 Prohibited List (via search; official PDF text not machine-readable), written 2026-11-06.

No sources yet

None of the three teachers' sources we have indexed discuss EPO yet. This page will fill in as sources are added.

Deeper guided audio lives on What Am I Appreciating Now (leaves this site, opens in a new tab). What Am I Appreciating Now is a separate site run by the same operator; it sells meditation and hypnosis sessions.

Disclaimer: for research purposes only

All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.

EPO — Hunter, Taylor, Bachmeyer | Reset Biology